{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:23:48Z","timestamp":1792592628063,"version":"4.5.0"},"reference-count":32,"publisher":"American Society of Hematology","issue":"1","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,14]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract:<\/jats:title>\n                  <jats:p>Hypofibrinolysis is a documented abnormality in conditions with high risk of vascular occlusion. A key inhibitor of fibrinolysis is \u03b12-antiplasmin (\u03b12AP), and we hypothesize that the Affimer technology, comprising small conformational proteins with 2 9-amino-acid variable regions, can be used to modulate \u03b12AP activity and facilitate fibrinolysis. Using a phage display system, a library of Affimers was screened against \u03b12AP. A total of 28 \u03b12AP-specific Affimers were isolated, of which 1, termed Affimer A11, inhibited protein function and enhanced fibrinolysis. Affimer A11 displayed a monomeric form and consistently reduced the lysis time of clots made from plasma samples of individuals with type 2 diabetes mellitus (n\u00a0=\u00a015; from 150.8\u00a0\u00b1 100.9 to 109.8\u00a0\u00b1 104.8\u00a0minutes) and those with cardiovascular disease (n\u00a0=\u00a015; 117.6\u00a0\u00b1 40.6 to 79.7\u00a0\u00b1 33.3\u00a0minutes; P\u00a0&amp;lt; .01 for both groups). The effects of A11 on fibrinolysis were maintained when clots were made from whole blood samples. Mechanistic studies demonstrated that A11 did not affect clot structure or interfere with the incorporation of \u03b12AP into fibrin networks but significantly enhanced plasmin activity and accelerated plasmin generation. Affimer A11 reduced \u03b12AP binding to plasmin(ogen), whereas molecular modeling demonstrated interactions with \u03b12AP in an area responsible for binding to plasminogen, explaining the effects on both plasmin activity and generation. Affimer A11, at 0.15 to 0.60\u00a0mg\/mL, had the ability to bind 70% to 90% of plasma \u03b12AP. In conclusion, we demonstrate that Affimers are viable tools for inhibiting \u03b12AP function and facilitating fibrinolysis, making them potential future therapeutic agents to reduce thrombosis risk.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014235","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T21:57:18Z","timestamp":1730930238000},"page":"89-100","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Use of Affimer technology for inhibition of \u03b12-antiplasmin and enhancement of fibrinolysis"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5041-5763","authenticated-orcid":false,"given":"Nikoletta","family":"Pechlivani","sequence":"first","affiliation":[{"name":"1Clinical Population and Sciences Department, Leeds Institute for Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basmah","family":"Alsayejh","sequence":"additional","affiliation":[{"name":"1Clinical Population and Sciences Department, Leeds Institute for Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, Leeds, United Kingdom"},{"name":"2Ministry of Education, Riyadh, Kingdom of Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansour","family":"Almutairi","sequence":"additional","affiliation":[{"name":"1Clinical Population and Sciences Department, Leeds Institute for Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, Leeds, United Kingdom"},{"name":"3General Directorate of Medical Services, Ministry of Interior, Riyadh, Kingdom of Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4846-9097","authenticated-orcid":false,"given":"Katie","family":"Simmons","sequence":"additional","affiliation":[{"name":"4Discovery and Translational Science Department, Leeds Institute for Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2859-4093","authenticated-orcid":false,"given":"Thembaninkosi","family":"Gaule","sequence":"additional","affiliation":[{"name":"1Clinical Population and Sciences Department, Leeds Institute for Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fladia","family":"Phoenix","sequence":"additional","affiliation":[{"name":"1Clinical Population and Sciences Department, Leeds Institute for Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5076-4450","authenticated-orcid":false,"given":"Noppadol","family":"Kietsiriroje","sequence":"additional","affiliation":[{"name":"1Clinical Population and Sciences Department, Leeds Institute for Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, Leeds, United Kingdom"},{"name":"5Endocrinology and Metabolism Unit, Faculty of Medicine, Prince of Songkla University, Hat-yai, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4452-7619","authenticated-orcid":false,"given":"Sreenivasan","family":"Ponnambalam","sequence":"additional","affiliation":[{"name":"6School of Molecular and Cellular Biology, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4870-6542","authenticated-orcid":false,"given":"C\u00e9dric","family":"Duval","sequence":"additional","affiliation":[{"name":"4Discovery and Translational Science Department, Leeds Institute for Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6310-5745","authenticated-orcid":false,"given":"Robert A.S.","family":"Ari\u00ebns","sequence":"additional","affiliation":[{"name":"1Clinical Population and Sciences Department, Leeds Institute for Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0280-4005","authenticated-orcid":false,"given":"Christian","family":"Tiede","sequence":"additional","affiliation":[{"name":"6School of Molecular and Cellular Biology, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4134-7484","authenticated-orcid":false,"given":"Darren C.","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"6School of Molecular and Cellular Biology, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1636-3725","authenticated-orcid":false,"given":"Ramzi A.","family":"Ajjan","sequence":"additional","affiliation":[{"name":"4Discovery and Translational Science Department, Leeds Institute for Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"issue":"12","key":"2025012115560736100_bib1","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1161\/ATVBAHA.111.230631","article-title":"Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases","volume":"31","author":"Undas","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"13","key":"2025012115560736100_bib2","first-page":"2999","article-title":"Fibrin clot properties in atherosclerotic vascular disease: from pathophysiology to clinical outcomes","volume":"10","author":"Zabczyk","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"5","key":"2025012115560736100_bib3","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1055\/s-0040-1718923","article-title":"Fibrinolysis in acute and chronic cardiovascular disease","volume":"47","author":"Kietsiriroje","year":"2021","journal-title":"Semin Thromb Hemost"},{"issue":"9","key":"2025012115560736100_bib4","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/jth.13033","article-title":"Engineering of plasminogen activators for targeting to thrombus and heightening thrombolytic efficacy","volume":"13","author":"Absar","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"issue":"11","key":"2025012115560736100_bib5","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nrcardio.2014.129","article-title":"Decade in review--acute coronary syndromes: successes and future objectives in acute coronary syndrome","volume":"11","author":"Van de Werf","year":"2014","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"2025012115560736100_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/2042098615572333","article-title":"Bleeding risk with systemic thrombolytic therapy for pulmonary embolism: scope of the problem","volume":"6","author":"Daley","year":"2015","journal-title":"Ther Adv Drug Saf"},{"issue":"4","key":"2025012115560736100_bib7","doi-asserted-by":"crossref","first-page":"e396","DOI":"10.1055\/a-1957-6817","article-title":"Plasmin inhibitor in health and diabetes: role of the protein as a therapeutic target","volume":"6","author":"Alsayejh","year":"2022","journal-title":"TH Open"},{"issue":"5","key":"2025012115560736100_bib8","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00125-006-0197-4","article-title":"Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus","volume":"49","author":"Dunn","year":"2006","journal-title":"Diabetologia"},{"issue":"4","key":"2025012115560736100_bib9","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1177\/1479164110383723","article-title":"Coagulation and fibrinolysis in diabetes","volume":"7","author":"Alzahrani","year":"2010","journal-title":"Diab Vasc Dis Res"},{"issue":"22","key":"2025012115560736100_bib10","doi-asserted-by":"crossref","first-page":"12537","DOI":"10.3390\/ijms222212537","article-title":"Fibrinogen and antifibrinolytic proteins: interactions and future therapeutics","volume":"22","author":"Pechlivani","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"11","key":"2025012115560736100_bib11","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1161\/CIRCULATIONAHA.116.024421","article-title":"Releasing the brakes on the fibrinolytic system in pulmonary emboli: unique effects of plasminogen activation and alpha2-antiplasmin inactivation","volume":"135","author":"Singh","year":"2017","journal-title":"Circulation"},{"issue":"1","key":"2025012115560736100_bib12","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1038\/s41467-021-24316-0","article-title":"RAS-inhibiting biologics identify and probe druggable pockets including an SII-alpha3 allosteric site","volume":"12","author":"Haza","year":"2021","journal-title":"Nat Commun"},{"issue":"505","key":"2025012115560736100_bib13","doi-asserted-by":"crossref","first-page":"eaaj2005","DOI":"10.1126\/scisignal.aaj2005","article-title":"Generation of specific inhibitors of SUMO-1- and SUMO-2\/3-mediated protein-protein interactions using Affimer (Adhiron) technology","volume":"10","author":"Hughes","year":"2017","journal-title":"Sci Signal"},{"issue":"11","key":"2025012115560736100_bib14","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood-2018-06-856195","article-title":"Affimer proteins as a tool to modulate fibrinolysis, stabilize the blood clot, and reduce bleeding complications","volume":"133","author":"Kearney","year":"2019","journal-title":"Blood"},{"key":"2025012115560736100_bib15","doi-asserted-by":"crossref","first-page":"e24903","DOI":"10.7554\/eLife.24903","article-title":"Affimer proteins are versatile and renewable affinity reagents","volume":"6","author":"Tiede","year":"2017","journal-title":"Elife"},{"issue":"505","key":"2025012115560736100_bib16","doi-asserted-by":"crossref","first-page":"eaan0868","DOI":"10.1126\/scisignal.aan0868","article-title":"Isolation of isoform-specific binding proteins (Affimers) by phage display using negative selection","volume":"10","author":"Tang","year":"2017","journal-title":"Sci Signal"},{"issue":"12","key":"2025012115560736100_bib17","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1161\/ATVBAHA.107.153221","article-title":"Heritability of clot formation, morphology, and lysis: the EuroCLOT study","volume":"27","author":"Carter","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"2025012115560736100_bib18","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1161\/ATVBAHA.115.306695","article-title":"Factor XIII A-subunit V34L variant affects thrombus cross-linking in a murine model of thrombosis","volume":"36","author":"Duval","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2025012115560736100_bib19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1006\/bbrc.1997.7718","article-title":"Glycated proteins modulate tissue-plasminogen activator-catalyzed plasminogen activation","volume":"240","author":"Bobbink","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"2025012115560736100_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nmeth.3213","article-title":"The I-TASSER suite: protein structure and function prediction","volume":"12","author":"Yang","year":"2015","journal-title":"Nat Methods"},{"issue":"16","key":"2025012115560736100_bib21","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J\u00a0Comput Chem"},{"issue":"13","key":"2025012115560736100_bib22","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/eurheartj\/ehy013","article-title":"Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy","volume":"39","author":"Sumaya","year":"2018","journal-title":"Eur Heart J"},{"issue":"3","key":"2025012115560736100_bib23","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1055\/s-0039-1701011","article-title":"Impaired fibrinolysis predicts adverse outcome in acute coronary syndrome patients with diabetes: a PLATO sub-study","volume":"120","author":"Sumaya","year":"2020","journal-title":"Thromb Haemost"},{"issue":"1-2","key":"2025012115560736100_bib24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0049-3848(80)90414-4","article-title":"Influence of alpha 2-plasmin inhibitor on adsorption of plasminogen to fibrin","volume":"19","author":"Aoki","year":"1980","journal-title":"Thromb Res"},{"issue":"2","key":"2025012115560736100_bib25","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1172\/JCI108784","article-title":"The behavior of alpha2-plasmin inhibitor in fibrinolytic states","volume":"60","author":"Aoki","year":"1977","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"2025012115560736100_bib26","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0049-3848(77)90142-6","article-title":"Inhibition of plasminogen binding to fibrin by alpha2-plasmin inhibitor","volume":"10","author":"Moroi","year":"1977","journal-title":"Thromb Res"},{"issue":"1","key":"2025012115560736100_bib27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/0304-4165(92)90092-9","article-title":"Plasminogen binding by alpha 2-antiplasmin and histidine-rich glycoprotein does not inhibit plasminogen activation at the surface of fibrin","volume":"1156","author":"Angles-Cano","year":"1992","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"2025012115560736100_bib28","doi-asserted-by":"crossref","first-page":"E72","DOI":"10.1073\/pnas.1707856115","article-title":"Affimer proteins inhibit immune complex binding to FcgammaRIIIa with high specificity through competitive and allosteric modes of action","volume":"115","author":"Robinson","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2025012115560736100_bib29","doi-asserted-by":"crossref","first-page":"14366","DOI":"10.1038\/s41598-017-14749-3","article-title":"Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity","volume":"7","author":"Park","year":"2017","journal-title":"Sci Rep"},{"issue":"5","key":"2025012115560736100_bib30","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.4049\/jimmunol.179.5.2952","article-title":"CD8+ T cell activation is governed by TCR-peptide\/MHC affinity, not dissociation rate","volume":"179","author":"Tian","year":"2007","journal-title":"J\u00a0Immunol"},{"issue":"1","key":"2025012115560736100_bib31","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1038\/s41467-022-31457-3","article-title":"Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space","volume":"13","author":"Makowski","year":"2022","journal-title":"Nat Commun"},{"key":"2025012115560736100_bib32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.bej.2018.06.003","article-title":"Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility","volume":"137","author":"Rabia","year":"2018","journal-title":"Biochem Eng J"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/1\/89\/2349824\/blooda_adv-2024-014235-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/1\/89\/2349824\/blooda_adv-2024-014235-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T16:02:30Z","timestamp":1737475350000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/1\/89\/525880\/Use-of-Affimer-technology-for-inhibition-of-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014235","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,27]]}}}